Agussalim A, Citrawati C, Adam A. Role of IgE cells in the exacerbation and management of asthma: An experimental study. World J Immunol 2025; 15(1): 111119 [DOI: 10.5411/wji.v15.i1.111119]
Corresponding Author of This Article
Agussalim Agussalim, DNS, Assistant Professor, Department of Nursing, Makassar Health Polytechnic, Jalan Banta Bantaeng, Makassar 92152, Sulawesi Selatan, Indonesia. salim170878@gmail.com
Research Domain of This Article
Allergy
Article-Type of This Article
Prospective Study
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Nov 18, 2025 (publication date) through Nov 23, 2025
Times Cited of This Article
Times Cited (0)
Journal Information of This Article
Publication Name
World Journal of Immunology
ISSN
2219-2824
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Share the Article
Agussalim A, Citrawati C, Adam A. Role of IgE cells in the exacerbation and management of asthma: An experimental study. World J Immunol 2025; 15(1): 111119 [DOI: 10.5411/wji.v15.i1.111119]
World J Immunol. Nov 18, 2025; 15(1): 111119 Published online Nov 18, 2025. doi: 10.5411/wji.v15.i1.111119
Role of IgE cells in the exacerbation and management of asthma: An experimental study
Agussalim Agussalim, Citrawati Citrawati, Adriyani Adam
Agussalim Agussalim, Department of Nursing, Makassar Health Polytechnic, Makassar 92152, Sulawesi Selatan, Indonesia
Citrawati Citrawati, Department of Midwifery, Makassar Health Polytechnic, Makassar 92152, Indonesia
Adriyani Adam, Department of Nutritionist, Makassar Health Polytechnic, Makassar 92152, Indonesia
Author contributions: Agussalim A contributed to conceptualization; project administration; methodology design; data curation; formal statistical analysis, manuscript drafting and critical revision; final approval of the manuscript; Citrawati C contributed to literature review; manuscript writing and editing, supervision of clinical data collection; Adam A contributed to oversight of laboratory and spirometry assessments, validation of immunologic assays, critical review of discussion and conclusion; proofreading and editing of the final version; all authors have read and approved the final manuscript and agree to be accountable for all aspects of the work.
Institutional review board statement: Approval from Health Research Ethics Committee–Poltekkes Kemenkes Makassar IRB Approval Number: EC/2785/2024.
Informed consent statement: All study participants, or their legal guardian, provided informed written consent prior to study enrollment.
Conflict-of-interest statement: The authors declare that there are no conflicts of interest regarding the publication of this paper.
CONSORT 2010 statement: The authors have read the CONSORT 2010 statement, and the manuscript was prepared and revised according to the CONSORT 2010 statement.
Data sharing statement: Data Sharing Statement: The data supporting the findings of this study are available from the corresponding author, Dr. Agussalim (salim170878@gmail.com), upon reasonable request. All shared data will be de-identified to protect participant confidentiality and will be provided solely for non-commercial academic and research purposes, following institutional and ethical approval.
Open Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Agussalim Agussalim, DNS, Assistant Professor, Department of Nursing, Makassar Health Polytechnic, Jalan Banta Bantaeng, Makassar 92152, Sulawesi Selatan, Indonesia. salim170878@gmail.com
Received: June 24, 2025 Revised: July 3, 2025 Accepted: October 29, 2025 Published online: November 18, 2025 Processing time: 146 Days and 19.8 Hours
Abstract
BACKGROUND
IgE plays a critical role in allergic inflammation and asthma pathogenesis. This study investigates the involvement of IgE cells in asthma exacerbation and evaluates the effectiveness of targeted interventions.
AIM
To evaluate the role of IgE in the exacerbation of allergic asthma and to determine the clinical efficacy of anti-IgE therapy in improving disease outcomes. Specifically, the study investigates changes in serum IgE levels, lung function, asthma control scores, and the frequency of acute exacerbations among patients receiving standard therapy with or without anti-IgE intervention.
METHODS
A total of 200 patients diagnosed with moderate to severe asthma were enrolled in this experimental study conducted from April 2024 to April 2025. Participants were randomized to receive either standard asthma therapy or therapy combined with anti-IgE agents. IgE levels and asthma control parameters were monitored.
RESULTS
Participants receiving anti-IgE treatment demonstrated a significant reduction in serum IgE levels (P < 0.001), improved Forced expiratory volume in one second scores, and fewer exacerbation episodes compared to the control group.
CONCLUSION
IgE cells significantly contribute to asthma severity, and targeted therapy against IgE can improve disease outcomes. These findings underscore the importance of immunomodulatory strategies in asthma management.
Core Tip: Asthma is a chronic respiratory disease driven in part by immune mechanisms involving IgE. This experimental study highlights the significant role of IgE in asthma exacerbation and demonstrates that anti-IgE therapy—specifically with omalizumab—can markedly reduce IgE levels, improve lung function, enhance asthma control, and decrease the frequency of exacerbations. These findings emphasize the clinical value of incorporating immunomodulatory strategies, particularly targeted anti-IgE interventions, into the treatment of moderate to severe allergic asthma.
